Cargando…

Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation

Infections due to meropenem-nonsusceptible bacterial strains (MNBSs) with meropenem minimum inhibitory concentrations (MICs) ≥ 16 mg/L have become an urgent problem. Currently, the optimal treatment strategy for these cases remains uncertain due to some limitations of currently available mono- and c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Xiangqing, Wu, Yi, Cao, Lizhi, Yao, Dunwu, Long, Minghui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895071/ https://www.ncbi.nlm.nih.gov/pubmed/31849910 http://dx.doi.org/10.3389/fmicb.2019.02777

Ejemplares similares

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
por: Wenzler, Eric, et al.
Publicado: (2020)

Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2021)

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
por: Deng, Guoliang, et al.
Publicado: (2023)

Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease
por: Hassanpour, Rezvan, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
por: Luque, Sonia, et al.
Publicado: (2021)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

The Evaluation of Meropenem Dosing Regimens Against ESBL-Producing Escherichia coli in ICU Patients Using Monte Carlo Simulation
por: Win, Ei Ei, et al.
Publicado: (2022)

1547. Modeling Pharmacokinetics and Pharmacodynamics of Meropenem Utilizing a Novel Infusion Method of Bolus to Prolonged Infusion
por: Moore, Sarah E, et al.
Publicado: (2019)

Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia
por: Alsultan, Abdullah, et al.
Publicado: (2021)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
por: Gan, Yuhong, et al.
Publicado: (2023)

2068. Evaluation of Ceftazidime-Avibactam Disks from Different Commercial Manufacturers for Susceptibility Testing against Meropenem Nonsusceptible Enterobacteriaceae
por: Lin, Lynn-Yao, et al.
Publicado: (2018)

Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Study, 2018 to 2019
por: Estabrook, Mark, et al.
Publicado: (2023)

Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis
por: Wu, Yue-E, et al.
Publicado: (2022)

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections
por: Lai, Chih-Cheng, et al.
Publicado: (2019)

202. Comparative Activity of Ceftazidime-Avibactam, Imipenem-Relebactam and Meropenem-Vaborbactam Tested Against Carbapenem-Nonsusceptible Enterobacterales that Are Carbapenemase-Negative
por: Castanheira, Mariana, et al.
Publicado: (2021)

Curcumin-meropenem synergy in carbapenem resistant Klebsiella pneumoniae curcumin-meropenem synergy
por: Gülen, Dumrul, et al.
Publicado: (2021)

Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation
por: Tanigawara, Yusuke, et al.
Publicado: (2011)

Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling
por: Kang, Soyoung, et al.
Publicado: (2022)

Meropenem: continuous or extended infusion?
por: Frippiat, Frédéric, et al.
Publicado: (2020)

Meropenem: Leucopenia: case report
Publicado: (2021)

Meropenem therapy in extracorporeal membrane oxygenation patients: an ongoing pharmacokinetic challenge
por: Honore, Patrick M., et al.
Publicado: (2015)

Population Pharmacokinetics of Vancomycin and Meropenem in Pediatric Extracorporeal Membrane Oxygenation Support
por: Zylbersztajn, Brenda, et al.
Publicado: (2021)

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
por: Abulfathi, Ahmed A., et al.
Publicado: (2021)

Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments
por: Liu, Yongge, et al.
Publicado: (2023)

Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem
por: Park, So Yeon, et al.
Publicado: (2019)

Population Pharmacokinetic Model and Dosing Simulation of Meropenem Using Measured Creatinine Clearance for Patients with Sepsis
por: Fukumoto, Shiori, et al.
Publicado: (2023)

In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019
por: Wise, Mark G., et al.
Publicado: (2023)

Pharmacokinetics of meropenem in intensive care patients receiving continuous renal replacement therapy
por: Giles, LJ, et al.
Publicado: (1998)

Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
por: Solé Violan, J, et al.
Publicado: (2014)

Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
por: Goncalves-Pereira, João, et al.
Publicado: (2014)

Pharmacokinetics of Meropenem in People with Cystic Fibrosis—A Proof of Concept Clinical Trial
por: Kamp, Jan C., et al.
Publicado: (2021)

Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study
por: Braune, Stephan, et al.
Publicado: (2018)

Meropenem-induced hypokalemia and metabolic alkalosis
por: Zaki, Syed Ahmed, et al.
Publicado: (2012)

The Radiostability of Meropenem Trihydrate in Solid State
por: Kilińska, Karolina, et al.
Publicado: (2018)

Impact of meropenem on Klebsiella pneumoniae metabolism
por: Foschi, Claudio, et al.
Publicado: (2018)

Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic/Pharmacodynamic Modeling and Monte Carlo Simulation
por: Alqahtani, Saeed, et al.
Publicado: (2021)

Clinical Outcomes and Safety of Meropenem–Colistin versus Meropenem–Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Park, Jae-Min, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study
por: Zhao, Hui-Ying, et al.
Publicado: (2017)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
por: Berrino, Pasquale Maria, et al.
Publicado: (2023)

Single-dose pharmacokinetics of meropenem in porcine cancellous bone determined by microdialysis: An animal study
por: Hanberg, Pelle, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r545msnho06eglo2ndi8nt1vsu